SEARCH

SEARCH BY CITATION

References

  • Aung, T., Chapuy, B., Vogel, D., Wenzel, D., Oppermann, M., Lahmann, M., Weinhage, T., Menck, K., Hupfeld, T., Koch, R., Trümper, L., Wulf, G.G., Lahmann, M., et al (2011) Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3. Proc Natl Acad Sci U S A, 108, 1533615341.
  • Avanzi, G.C., Lista, P., Giovinazzo, B., Miniero, R., Saglio, G., Benetton, G., Coda, R., Cattoretti, G. & Pegoraro, L. (1988) Selective growth response to IL-3 of a human leukaemic cell line with megakaryoblastic features. British Journal of Haematology, 69, 359366.
  • Besnard, V., Xu, Y. & Whitsett, J.A. (2007) Sterol response element binding protein and thyroid transcription factor-1 (Nkx2.1) regulate Abca3 gene expression. Am J Physiol Lung Cell Mol Physiol, 293, L1395L1405.
  • Bhatia, R., Holtz, M., Niu, N., Gray, R., Snyder, D.S., Sawyers, C.L., Arber, D.A., Slovak, M.L., Forman, S.J., et al (2003) Persistence of malignant haematopoietic progenitors in chronic myelogenous leukaemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood, 101, 47014707.
  • Burger, H., van Tol, H., Boersma, A.W., Brok, M., Wiemer, E.A., Stoter, G., Nooter, K., et al (2004) Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood, 104, 29402942.
  • Chapuy, B., Koch, R., Radunski, U., Corsham, S., Cheong, N., Inagaki, N., Ban, N., Wenzel, D., Reinhardt, D., Zapf, A., Schweyer, S., Klapper, W., Truemper, L., Wulf, G.G., et al (2008) Intracellular ABC transporter A3 confers multidrug resistance in leukaemia cells by lysosomal drug sequestration. Leukaemia, 22, 15761586.
  • Chu, S., Xu, H., Shah, N.P., Snyder, D.S., Forman, S.J., Sawyers, C.L. & Bhatia, R. (2005) Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukaemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood, 105, 20932098.
  • Chu, S., McDonald, T., Lin, A., Chakraborty, S., Huang, Q., Snyder, D.S., Bhatia, R., et al (2011) Persistence of leukaemia stem cells in chronic myelogenous leukaemia patients in prolonged remission with imatinib treatment. Blood, 118, 55655572.
  • Corbin, A.S., Agarwal, A., Loriaux, M., Cortes, J., Deininger, M.W. & Druker, B.J. (2011) Human chronic myeloid leukaemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest, 121, 396409.
  • Cortes, J., O'Brien, S. & Kantarjian, H. (2004) Discontinuation of imatinib therapy after achieving a molecular response. Blood, 104, 22042205.
  • Davies, A., Jordanides, N.E., Giannoudis, A., Lucas, C.M., Hatziieremia, S., Harris, R.J., Jørgensen, H.G., Holyoake, T.L., Pirmohamed, M., Clark, R.E., Mountford, J.C., Harris, R.J., et al (2009) Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukaemia cells is not mediated by active uptake or efflux by major drug transporters. Leukaemia, 23, 19992006.
  • Denizot, F. & Lang, R. (1986) Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. Journal of Immunological Methods, 89, 271277.
  • Dohse, M., Scharenberg, C., Shukla, S., Robey, R.W., Wolmann, T., Deeken, J.F., Brendel, C., Ambudkar, S.V., Neubauer, A., Bates, S.E., Deeken, J.F., et al (2010) Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metabolism and Disposition, 38, 13711380.
  • Druker, B.J., Guilhot, F., O'Brien, S.G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M.W., Silver, R.T., Goldman, J.M., Stone, R.M., Cervantes, F., Hochhaus, A., Powell, B.L., Gabrilove, J.L., Rousselot, P., Reiffers, J., Cornelissen, J.J., Hughes, T., Agis, H., Fischer, T., Verhoef, G., Shepherd, J., Saglio, G., Gratwohl, A., Nielsen, J.L., Radich, J.P., Simonsson, B., Taylor, K., Baccarani, M., So, C., Letvak, L., Larson, R.A., et al (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukaemia. N Engl J Med, 355, 24082417.
  • Fernández de Mattos, S., Essafi, A., Soeiro, I., Pietersen, A.M., Birkenkamp, K.U., Edwards, C.S., Martino, A., Nelson, B.H., Francis, J.M., Jones, M.C., Brosens, J.J., Coffer, P.J., Lam, E.W., Fernandez de, M.S., Essafi, A., Soeiro, I., Pietersen, A.M., Birkenkamp, K.U., Edwards, C.S., et al (2004) FoxO3a and BCR-ABL regulate cyclin D2 transcription through a STAT5/BCL6-dependent mechanism. Mol Cell Biol, 24, 1005810071.
  • Gorre, M.E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P.N., Sawyers, C.L., et al (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science, 293, 876880.
  • Graham, S.M., Jorgensen, H.G., Allan, E., Pearson, C., Alcorn, M.J., Richmond, L., Holyoake, T.L., et al (2002) Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukaemia are insensitive to STI571 in vitro. Blood, 99, 319325.
  • Hamilton, A., Helgason, G.V., Schemionek, M., Zhang, B., Myssina, S., Allan, E.K., Nicolini, F.E., Müller-Tidow, C., Bhatia, R., Brunton, V.G., Koschmieder, S., Holyoake, T.L., et al (2011) Chronic myeloid leukaemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood, 119, 15011510.
  • Heaney, N.B., Pellicano, F., Zhang, B., Crawford, L., Chu, S., Kazmi, S.M., Allan, E.K., Jorgensen, H.G., Irvine, A.E., Bhatia, R., Holyoake, T.L., et al (2010) Bortezomib induces apoptosis in primitive chronic myeloid leukaemia cells including LTC-IC and NOD/SCID repopulating cells. Blood, 115, 22412250.
  • Hiwase, D.K., White, D.L., Powell, J.A., Saunders, V.A., Zrim, S.A., Frede, A.K., Guthridge, M.A., Lopez, A.F., D'Andrea, R.J., To, L.B., Melo, J.V., Kumar, S., Hughes, T.P., et al (2010) Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors. Leukaemia, 24, 771778.
  • Holyoake, T., Jiang, X., Eaves, C. & Eaves, A. (1999) Isolation of a highly quiescent subpopulation of primitive leukaemic cells in chronic myeloid leukaemia. Blood, 94, 20562064.
  • Horn, M., Loeffler, M. & Roeder, I. (2008) Mathematical modeling of genesis and treatment of chronic myeloid leukaemia. Cells Tissues Organs, 188, 236247.
  • Houghton, P.J., Germain, G.S., Harwood, F.C., Schuetz, J.D., Stewart, C.F., Buchdunger, E., Traxler, P., et al (2004) Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Research, 64, 23332337.
  • Jeong, H.W., Cui, W., Yang, Y., Lu, J., He, J., Li, A., Song, D., Guo, Y., Liu, B.H., Chai, L., et al (2011) SALL4, a stem cell factor, affects the side population by regulation of the ATP-binding cassette drug transport genes. PLoS One, 6, e1837.
  • Kantarjian, H., Shah, N.P., Hochhaus, A., Cortes, J., Shah, S., Ayala, M., Moiraghi, B., Shen, Z., Mayer, J., Pasquini, R., Nakamae, H., Huguet, F., Boqué, C., Chuah, C., Bleickardt, E., Bradley-Garelik, M.B., Zhu, C., Szatrowski, T., Shapiro, D., Baccarani, M., et al (2010) Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia. N Engl J Med, 362, 22602270.
  • Lu, J., Ma, Y., Kong, N., Alipio, Z., Gao, C., Krause, D.S., Silberstein, L.E., Chai, L., et al (2011) Dissecting the role of SALL4, a newly identified stem cell factor, in chronic myelogenous leukaemia. Leukaemia, 25, 12111213.
  • Ma, Y., Cui, W., Yang, J., Qu, J., Di, C., Amin, H.M., Lai, R., Ritz, J., Krause, D.S., Chai, L., et al (2006) SALL4, a novel oncogene, is constitutively expressed in human acute myeloid leukaemia (AML) and induces AML in transgenic mice. Blood, 108, 27262735.
  • Mahon, F.X., Réa, D., Guilhot, J., Guilhot, F., Huguet, F., Nicolini, F., Legros, L., Charbonnier, A., Guerci, A., Varet, B., Etienne, G., Reiffers, J., Rousselot, P., et al (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol, 11, 10291035.
  • Nakanishi, T., Shiozawa, K., Hassel, B.A. & Ross, D.D. (2006) Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression. Blood, 108, 678684.
  • Preudhomme, C., Guilhot, J., Nicolini, F.E., Guerci-Bresler, A., Rigal-Huguet, F., Maloisel, F., Coiteux, V., Gardembas, M., Berthou, C., Vekhoff, A., Rea, D., Jourdan, E., Allard, C., Delmer, A., Rousselot, P., Legros, L., Berger, M., Corm, S., Etienne, G., Roche-Lestienne, C., Eclache, V., Mahon, F.X., Guilhot FPreudhomme, C., Guilhot, J., Nicolini, F.E., Guerci-Bresler, A., Rigal-Huguet, F., Maloisel, F., et al (2010) Imatinib plus peginterferon alfa-2a in chronic myeloid leukaemia. N Engl J Med, 363, 25112521.
  • Roeder, I., Horn, M., Glauche, I., Hochaus, A., Mueller, M.C. & Loeffler, M. (2006) Dynamic modeling of imatinib-treated chronic myeloid leukaemia: functional insights and clinical implications. Nat Med, 12, 11811184.
  • Saglio, G., Kim, D.W., Issaragrisil, S., le Coutre, P., Etienne, G., Lobo, C., Pasquini, R., Clark, R.E., Hochhaus, A., Hughes, T.P., Gallagher, N., Hoenekopp, A., Dong, M., Haque, A., Larson, R.A., Kantarjian HMSaglio, G., Kim, D.W., Issaragrisil, S., Le Coutre, P., Etienne, G., Lobo, C., et al (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukaemia. N Engl J Med, 362, 22512259.
  • Shulenin, S., Nogee, L.M., Annilo, T., Wert, S.E., Whitsett, J.A. & Dean, M. (2004) ABCA3 gene mutations in newborns with fatal surfactant deficiency. N Engl J Med, 350, 12961303.
  • Wulf, G.G., Wang, R.Y., Kuehnle, I., Weidner, D., Marini, F., Brenner, M.K., Andreeff, M. & Goodell, M.A. (2001) A leukaemic stem cell with intrinsic drug efflux capacity in acute myeloid leukaemia. Blood, 98, 11661173.
  • Wulf, G.G., Modlich, S., Inagaki, N., Reinhardt, D., Schroers, R., Griesinger, F., Trumper, L., et al (2004) ABC transporter ABCA3 is expressed in acute myeloid leukaemia blast cells and participates in vesicular transport. Haematologica, 89, 13951397.
  • Yang, J., Chai, L., Gao, C., Fowles, T.C., Alipio, Z., Dang, H., Xu, D., Fink, L.M., Ward, D.C., Ma, Y., et al (2008) Genome-wide analysis reveals Sall4 to be a major regulator of pluripotency in murine-embryonic stem cells. Proc Natl Acad Sci U S A, 105, 1975619761.
  • Yang, J., Gao, C., Chai, L. & Ma, Y. (2010) A novel SALL4/OCT4 transcriptional feedback network for pluripotency of embryonic stem cells. PLoS One, 5, e10766.
  • Zhang, G. & Fu, Y. (2006) Antiproliferative effect of indomethacin on CML cells is related to the suppression of STATs/Bcl-XL signal pathway. Ann Hematol, 85, 443449.
  • Zhang, B., Strauss, A.C., Chu, S., Li, M., Ho, Y., Shiang, K.D., Snyder, D.S., Huettner, C.S., Shultz, L., Holyoake, T., Bhatia, R., et al (2010) Effective targeting of quiescent chronic myelogenous leukaemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Cancer Cell, 17, 427442.